New combo shows promise for rare blood cancer, may limit lifelong treatment
NCT ID NCT04463953
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of three drugs (zanubrutinib, ixazomib, and dexamethasone) in 25 people newly diagnosed with Waldenström macroglobulinemia, a rare blood cancer. The treatment was given for up to 24 months and then stopped, aiming to achieve deep remission and reduce the need for lifelong therapy. The goal was to see if this time-limited approach could improve outcomes compared to standard treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WALDENSTRÖM MACROGLOBULINEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, 300020, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug duo shows promise for rare blood cancer
- New PET tracer aims to spot hidden cancers without biopsy
- New hope for rare blood cancer: targeted drug shows promise in early trial
- New Two-Step transplant shows promise for blood cancer patients
- New drug targets Hard-to-Treat blood cancers in chinese trial
- New drug combo shows promise for blood cancer patients